OurPharma LLC Terminates Class III Recall for Superpotent HYDROmorphone HCl
OurPharma LLC has concluded a Class III voluntary recall (D-0385-2025) for 1,375 cassettes of superpotent HYDROmorphone Hydrochloride 50mg/50mL, manufactured at its Fayetteville, AR facility. This event, initiated April 15, 2025, and terminated March 6, 2026, highlights critical quality control vulnerabilities in compounded sterile products. Procurement and regulatory teams must scrutinize supplier potency testing protocols to mitigate supply chain risks.
OurPharma LLC's Class III Recall for Superpotent HYDROmorphone HCl: A Critical Quality Failure
On April 15, 2025, OurPharma LLC initiated a voluntary Class III recall, D-0385-2025, for its HYDROmorphone Hydrochloride 50mg/50mL (1mg/mL) product, packaged in 50 mL cassettes. This action, originating from OurPharma's facility at 2512 S City Lake Rd, Fayetteville, AR 72701-5013, United States, was prompted by findings that the assay/potency result for hydromorphone HCl in a compounded stability lot was higher than specified limits, rendering the drug superpotent. For procurement directors, this signifies a critical breakdown in quality control processes, particularly concerning compounded sterile products where precise dosing is paramount. A superpotent drug carries inherent risks, potentially leading to overdose or adverse patient reactions, which can translate into significant reputational damage and liability for downstream distributors and healthcare providers. The recall affected 1,375 cassettes distributed nationwide in the USA, encompassing multiple lot numbers (e.g., 104024120001, 104025010002) with expiration dates ranging from June 2025 to July 2025. This broad distribution pattern underscores the potential for widespread impact on patient care and supply chain continuity, necessitating immediate action from all stakeholders involved in the distribution network of NDC 73013-1040-01.
Strategic Implications of Terminated Recalls for Pharmaceutical Supply Chain Resilience
The termination of OurPharma LLC's recall on March 6, 2026, indicates that the company has successfully completed all necessary corrective actions, including product retrieval and addressing the root cause of the superpotency, to the satisfaction of the FDA. For regulatory affairs heads, this termination provides a benchmark for evaluating supplier responsiveness and the efficacy of their quality management systems in resolving significant deviations. While a Class III classification implies that adverse health consequences are unlikely, the event still underscores the imperative for robust supplier qualification and ongoing monitoring. Business development executives should view such events as opportunities to reassess their partner portfolios, prioritizing manufacturers with impeccable compliance records and advanced quality assurance protocols, especially for high-risk compounded injectables like HYDROmorphone Hydrochloride. The voluntary nature of OurPharma's recall suggests internal detection or proactive engagement with regulatory bodies, which can be a positive indicator of a firm's commitment to quality, despite the initial lapse. However, the incident serves as a stark reminder for all supply chain VPs that even terminated recalls necessitate a thorough review of supplier audit trails, stability data, and batch release criteria to prevent similar disruptions and safeguard patient safety.